EVALUATION OF TREATMENT EFFICACY IN PATIENTS WITH NON-ALCOHOLIC-STEATOHEPATITIS AND HETEROZYGOTIC FAMILIAL HYPERCHOLESTEROLEMIA.
The aim of the study was to increase the efficacy of treatment of patients with HFHC and NASH by developing a personified approach to the therapy with rosuvastatin 20 mg/day and combined hepatoprotector at the inpatient and outpatient stages of treatment. 124 patients with clinical HFHC were examined. The object of the study was 55 patients (age 55.45±5.5 years) with a clinical diagnosis of HFHC, NASH. All patients underwent a detailed physical examination, laboratory-instrumental (general clinical, biochemical (hepatic transaminases, lipidogram, ultrasonography of the abdominal organs), molecular genetic examination (polymorphism of the SLCO1B1 gene). Two groups of study were formed, in the first group patients received rosuvastatin 20 mg/day, in the second group - rozuvastatin 20 mg/day and combined hepatoprotector 2 capsules 3 times a day for 90 days. The patients treated with rosuvastatin 20 mg/day and hepatoprotector were revealed a reliable decrease in the level of TC by 46%, which was 5.1±0.59 mmol/l (p<0.005), the level of LDL significantly decreased by 68.5% - 2.23±0.58 mmol/l (p<0.005), the level of HDL increased by 73% and amounted to 2.56±0.29 mmol/l (p<0.005). On the 90th day of therapy, the activity of hepatic transaminases reached reference values: ALT 32.16±7.83 units/l, AST - 30.11±6.32 units/l (p<0.005). Based on the complex examination and determination of polymorphism of SLCO1B1, a personified dose of statin was selected.